Literature DB >> 12195423

BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.

Anne-Renee Hartman1, James M Ford.   

Abstract

Inheritance of a mutation in the gene BRCA1 confers on women a 50-85% lifetime risk of developing breast cancer. Mutations in the TP53 tumor-suppressor gene are found in 70-80% of BRCA1-mutated breast cancer but only 30% of those with wildtype BRCA1 (ref. 3). The p53 protein regulates nucleotide excision repair (NER) through transcriptional regulation of genes involved in the recognition of adducts in genomic DNA. Loss of p53 function results in deficient global genomic repair (GGR), a subset of NER that targets and removes lesions from the whole genome. Here we show that BRCA1 specifically enhances the GGR pathway, independent of p53, and can induce p53-independent expression of the NER genes XPC, DDB2, and GADD45. Defects in the NER pathway in BRCA1-associated breast cancers may be causal in tumor development, suggesting a multistep model of carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195423     DOI: 10.1038/ng953

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  71 in total

1.  BRCA1 is required for postreplication repair after UV-induced DNA damage.

Authors:  Shailja Pathania; Jenna Nguyen; Sarah J Hill; Ralph Scully; Guillaume O Adelmant; Jarrod A Marto; Jean Feunteun; David M Livingston
Journal:  Mol Cell       Date:  2011-09-29       Impact factor: 17.970

2.  Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.

Authors:  Tatsuyuki Chiyoda; Peter C Hart; Mark A Eckert; Stephanie M McGregor; Ricardo R Lastra; Ryuji Hamamoto; Yusuke Nakamura; S Diane Yamada; Olufunmilayo I Olopade; Ernst Lengyel; Iris L Romero
Journal:  Cancer Prev Res (Phila)       Date:  2017-03-06

Review 3.  Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response.

Authors:  H Christian Reinhardt; Michael B Yaffe
Journal:  Nat Rev Mol Cell Biol       Date:  2013-09       Impact factor: 94.444

Review 4.  BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

Authors:  Amal Aly; Shridar Ganesan
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

Review 5.  Nucleotide excision repair in humans.

Authors:  Graciela Spivak
Journal:  DNA Repair (Amst)       Date:  2015-09-10

6.  Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma.

Authors:  Gustavo Baldassarre; Sabrina Battista; Barbara Belletti; Sanjay Thakur; Francesca Pentimalli; Francesco Trapasso; Monica Fedele; Giovanna Pierantoni; Carlo M Croce; Alfredo Fusco
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

7.  A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Authors:  Bastiaan Evers; Eva Schut; Eline van der Burg; Tanya M Braumuller; David A Egan; Henne Holstege; Pauline Edser; David J Adams; Richard Wade-Martins; Peter Bouwman; Jos Jonkers
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability.

Authors:  Ellen E McCarthy; Julide T Celebi; Richard Baer; Thomas Ludwig
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  Pyrimidine base damage is increased in women with BRCA mutations.

Authors:  Edwin E Budzinski; Helen B Patrzyc; Jean B Dawidzik; Harold G Freund; Peter Frederick; Heidi E Godoy; Nicoleta C Voian; Kunle Odunsi; Harold C Box
Journal:  Cancer Lett       Date:  2013-04-11       Impact factor: 8.679

10.  Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.

Authors:  Stephen G Grant; Rubina Das; Christina M Cerceo; Wendy S Rubinstein; Jean J Latimer
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.